Progyny Inc
NASDAQ:PGNY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (26.2), the stock would be worth $39.31 (117% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12.1 | $18.12 |
0%
|
| 3-Year Average | 26.2 | $39.31 |
+117%
|
| 5-Year Average | 73.1 | $109.5 |
+504%
|
| Industry Average | 19.2 | $28.83 |
+59%
|
| Country Average | 19.6 | $29.39 |
+62%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$1.2B
|
/ |
Jan 2026
$90.9m
|
= |
|
|
$1.2B
|
/ |
Dec 2026
$192.4m
|
= |
|
|
$1.2B
|
/ |
Dec 2027
$217.4m
|
= |
|
|
$1.2B
|
/ |
Dec 2028
$288.8m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Progyny Inc
NASDAQ:PGNY
|
1.5B USD | 12.1 | 25.3 | |
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
294.1B USD | 0 | 24.4 | |
| US |
A
|
Anthem Inc
LSE:0HG8
|
83.9B USD | 0 | 14.8 | |
| US |
|
Elevance Health Inc
NYSE:ELV
|
71.3B USD | 0 | 12.6 | |
| US |
|
Humana Inc
NYSE:HUM
|
24.7B USD | 0 | 20.8 | |
| US |
|
Centene Corp
NYSE:CNC
|
18.8B USD | 0 | -2.8 | |
| US |
|
Molina Healthcare Inc
NYSE:MOH
|
7.6B USD | 4.3 | 16.1 | |
| US |
|
Healthequity Inc
NASDAQ:HQY
|
7.3B USD | 24 | 34 | |
| US |
M
|
Magellan Health Inc
F:MAH1
|
2.2B EUR | 38.5 | 8.5 | |
| BR |
|
Odontoprev SA
BOVESPA:ODPV3
|
8.6B BRL | 10.8 | 14.8 | |
| BR |
|
Hapvida Participacoes e Investimentos SA
BOVESPA:HAPV3
|
5.9B BRL | 5.9 | -41.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Progyny Inc
Glance View
In a world where the concept of family is continually evolving, Progyny Inc. emerges as a pioneer, reshaping the landscape of fertility and family-building benefits. Founded with a mission to offer comprehensive fertility solutions, the company leverages a unique combination of personalized concierge service and cutting-edge technology to meet the growing demand for reproductive health services. Progyny's role in the industry is substantial, providing a suite of tailored benefits that include fertility treatments, egg freezing, genetic testing, and support services. Through its proprietary Smart Cycle plan, Progyny stands apart by integrating these services into a single, streamlined benefits package, reducing complexities and elevating the experience for patients and employers alike. The heart of Progyny's business model lies in its collaboration with employers, offering them the opportunity to include comprehensive fertility benefits as part of their health packages. By doing so, Progyny opens the door for companies to attract and retain talent in a competitive workforce, ensuring employees have access to vital reproductive assistance. The company generates revenue by partnering with these employers, who pay for the fertility benefits as part of their employee health plans. This innovative approach not only ensures recurring income for Progyny but also aligns the company’s success with positive health outcomes for its clients. As more organizations recognize the value in supporting employees' family-building journeys, Progyny’s influence and relevance in the market continue to grow, reinforcing its standing as a leader in fertility solutions.